MX2022010568A - Métodos y composiciones que usan nanoportadores sintéticos que comprenden inmunosupresor. - Google Patents

Métodos y composiciones que usan nanoportadores sintéticos que comprenden inmunosupresor.

Info

Publication number
MX2022010568A
MX2022010568A MX2022010568A MX2022010568A MX2022010568A MX 2022010568 A MX2022010568 A MX 2022010568A MX 2022010568 A MX2022010568 A MX 2022010568A MX 2022010568 A MX2022010568 A MX 2022010568A MX 2022010568 A MX2022010568 A MX 2022010568A
Authority
MX
Mexico
Prior art keywords
immunosuppressant
methods
compositions
synthetic nanocarriers
nanocarriers
Prior art date
Application number
MX2022010568A
Other languages
English (en)
Inventor
Petr Ilyinskii
Takashi Kei Kishimoto
Original Assignee
Selecta Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/028132 external-priority patent/WO2021211100A1/en
Application filed by Selecta Biosciences Inc filed Critical Selecta Biosciences Inc
Publication of MX2022010568A publication Critical patent/MX2022010568A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan en la presente métodos y composiciones relacionados con nanoportadores sintéticos que comprenden un inmunosupresor que pueden usarse, por ejemplo, para inducir autofagia y/o promover un fenotipo tolerógeno.
MX2022010568A 2020-02-26 2021-02-26 Métodos y composiciones que usan nanoportadores sintéticos que comprenden inmunosupresor. MX2022010568A (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202062981584P 2020-02-26 2020-02-26
US202062981612P 2020-02-26 2020-02-26
US202062981602P 2020-02-26 2020-02-26
US202062981586P 2020-02-26 2020-02-26
US202062981594P 2020-02-26 2020-02-26
US202062981606P 2020-02-26 2020-02-26
US202062981595P 2020-02-26 2020-02-26
US202062981589P 2020-02-26 2020-02-26
PCT/US2020/028132 WO2021211100A1 (en) 2020-04-14 2020-04-14 Methods and compositions for inducing autophagy
PCT/US2021/019927 WO2021174013A1 (en) 2020-02-26 2021-02-26 Methods and compositions using synthetic nanocarriers comprising immunosuppressant

Publications (1)

Publication Number Publication Date
MX2022010568A true MX2022010568A (es) 2022-11-30

Family

ID=74947602

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010568A MX2022010568A (es) 2020-02-26 2021-02-26 Métodos y composiciones que usan nanoportadores sintéticos que comprenden inmunosupresor.

Country Status (10)

Country Link
US (1) US20210290601A1 (es)
EP (1) EP4110334A1 (es)
JP (1) JP2023515202A (es)
KR (1) KR20220146559A (es)
CN (1) CN115379839A (es)
AU (1) AU2021225955A1 (es)
CA (1) CA3173734A1 (es)
IL (1) IL295868A (es)
MX (1) MX2022010568A (es)
WO (1) WO2021174013A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA027259B1 (ru) 2011-04-29 2017-07-31 Селекта Байосайенсиз, Инк. Наноносители, вырабатывающие иммунную толерантность, для антиген-специфического удаления т-эффекторных клеток
CN105263478A (zh) 2013-05-03 2016-01-20 西莱克塔生物科技公司 用于诱导免疫耐受的具有特定药效学有效持续期之免疫抑制剂与抗原的递送
US11426451B2 (en) 2017-03-11 2022-08-30 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with antiinflammatories and synthetic nanocarriers comprising an immunosuppressant
CN114207440A (zh) 2019-06-04 2022-03-18 西莱克塔生物科技公司 聚乙二醇化尿酸酶的制剂和剂量
CA3180166A1 (en) * 2020-04-14 2021-10-21 Selecta Biosciences, Inc. Methods and compositions for inducing autophagy
ES2986744A1 (es) * 2023-04-13 2024-11-12 Servicio Andaluz De Salud Rapamicina y estatinas como protectores frente daño hepático
CN117860782B (zh) * 2024-03-11 2024-05-28 中国康复科学所(中国残联残疾预防与控制研究中心) 双阴性t细胞在制备治疗脊髓损伤的药物中的用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946929A (en) 1983-03-22 1990-08-07 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4806621A (en) 1986-01-21 1989-02-21 Massachusetts Institute Of Technology Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article
CA1340581C (en) 1986-11-20 1999-06-08 Joseph P. Vacanti Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices
US5759830A (en) 1986-11-20 1998-06-02 Massachusetts Institute Of Technology Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo
US5736372A (en) 1986-11-20 1998-04-07 Massachusetts Institute Of Technology Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure
US5019379A (en) 1987-07-31 1991-05-28 Massachusetts Institute Of Technology Unsaturated polyanhydrides
US5010167A (en) 1989-03-31 1991-04-23 Massachusetts Institute Of Technology Poly(amide-and imide-co-anhydride) for biological application
US5399665A (en) 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
US5843452A (en) * 1992-11-09 1998-12-01 Pharmagenesis, Inc. Immunotherapy composition and method
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
US5514378A (en) 1993-02-01 1996-05-07 Massachusetts Institute Of Technology Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5716404A (en) 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US6123727A (en) 1995-05-01 2000-09-26 Massachusetts Institute Of Technology Tissue engineered tendons and ligaments
US6095148A (en) 1995-11-03 2000-08-01 Children's Medical Center Corporation Neuronal stimulation using electrically conducting polymers
US5902599A (en) 1996-02-20 1999-05-11 Massachusetts Institute Of Technology Biodegradable polymer networks for use in orthopedic and dental applications
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US5837752A (en) 1997-07-17 1998-11-17 Massachusetts Institute Of Technology Semi-interpenetrating polymer networks
US6632922B1 (en) 1998-03-19 2003-10-14 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6686446B2 (en) 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6506577B1 (en) 1998-03-19 2003-01-14 The Regents Of The University Of California Synthesis and crosslinking of catechol containing copolypeptides
CA2400172C (en) 2000-02-28 2010-04-20 Genesegues, Inc. Nanocapsule encapsulation system and method
GB0025414D0 (en) 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
US6818732B2 (en) 2001-08-30 2004-11-16 The Regents Of The University Of California Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers
US8263129B2 (en) 2003-12-19 2012-09-11 The University Of North Carolina At Chapel Hill Methods for fabricating isolated micro-and nano-structures using soft or imprint lithography
JP2008512350A (ja) 2004-07-01 2008-04-24 イェール ユニバーシティ 標的化され、そして高密度で薬物が負荷されるポリマー性物質
AU2008239795A1 (en) 2007-04-12 2008-10-23 Emory University Novel strategies for delivery of active agents using micelles and particles
EP2217269B1 (en) 2007-10-12 2017-04-12 Massachusetts Institute of Technology Vaccine nanotechnology
CN101676291B (zh) 2008-09-18 2012-05-09 上海海和药物研究开发有限公司 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
EA027259B1 (ru) * 2011-04-29 2017-07-31 Селекта Байосайенсиз, Инк. Наноносители, вырабатывающие иммунную толерантность, для антиген-специфического удаления т-эффекторных клеток
CN105263478A (zh) * 2013-05-03 2016-01-20 西莱克塔生物科技公司 用于诱导免疫耐受的具有特定药效学有效持续期之免疫抑制剂与抗原的递送
US20150359865A1 (en) * 2014-06-17 2015-12-17 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for t-cell-mediated autoimmune disease
BR112017008499B1 (pt) 2014-11-05 2023-10-03 Selecta Biosciences, Inc Composições compreendendo nanoveículos sintéticos, seus usos, método para produzir os mesmos e kit
WO2017139212A1 (en) * 2016-02-08 2017-08-17 Cyta Therapeutics, Inc. Particle delivery of rapamycin to the liver
MX2020003838A (es) * 2017-10-13 2020-08-06 Selecta Biosciences Inc Metodos y composiciones para atenuar las respuestas de inmunoglobulina m del vector de transferencia antiviral.
EP4048269A1 (en) * 2019-10-21 2022-08-31 Selecta Biosciences, Inc. Methods and compositions for treating liver diseases and disorders
CA3180166A1 (en) * 2020-04-14 2021-10-21 Selecta Biosciences, Inc. Methods and compositions for inducing autophagy
WO2023133319A1 (en) * 2022-01-10 2023-07-13 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
WO2023183568A1 (en) * 2022-03-25 2023-09-28 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents
US20230381277A1 (en) * 2022-04-08 2023-11-30 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance

Also Published As

Publication number Publication date
CA3173734A1 (en) 2021-09-02
CN115379839A (zh) 2022-11-22
KR20220146559A (ko) 2022-11-01
JP2023515202A (ja) 2023-04-12
IL295868A (en) 2022-10-01
US20210290601A1 (en) 2021-09-23
EP4110334A1 (en) 2023-01-04
WO2021174013A1 (en) 2021-09-02
AU2021225955A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
MX2022010568A (es) Métodos y composiciones que usan nanoportadores sintéticos que comprenden inmunosupresor.
PH12022550469A1 (en) Kras g12d inhibitors
MX2021000285A (es) Composiciones que comprenden cepas bacterianas.
EP4445955A3 (en) Formulations and doses of pegylated uricase
MY209471A (en) Interleukin-2 agents and uses thereof
MX2025010681A (es) Formulaciones transdermicas
MX2020008542A (es) Composiciones y métodos para el suministro de proteínas membranales.
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
CY1125211T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
MY209474A (en) Il-2 conjugates and methods of use to treat autoimmune diseases
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
EA201890996A1 (ru) Способ получения t-клеток для т-клеточной терапии
MX2022004983A (es) Composiciones de profarmaco y metodos de tratamiento.
MY201811A (en) Method of reducing neutropenia
PH12020551637A1 (en) Additives for protein formulations to improve thermal stability
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
GEP20247585B (en) Furoindazole derivatives
MX2022005506A (es) Formulaciones y dosis de uricasa pegilada.
MX2020011817A (es) Metodos para tratar el linfoma.
MX2024005310A (es) Composiciones para el tratamiento de la perdida del cabello.
MY209035A (en) Tricyclic compounds and their use
ZA202109829B (en) Super-oxide dismutase soluble fiber compositions
MX2022006312A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.